ERBB2 and gastric cancer: This randomized, double-blind, placebo-controlled phase 2 trial was designed to evaluate the bemarituzumab-mFOLFOX6 combination in patients with HER-2 non-positive, FGFR2b-selected, treatment-naïve advanced GC.